|

REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

RECRUITINGSponsored by Medtronic Cardiovascular
Actively Recruiting
SponsorMedtronic Cardiovascular
Started2025-02-06
Est. completion2029-03
Eligibility
Age18 Years – 105 Years
Healthy vol.Accepted
Locations70 sites
View on ClinicalTrials.gov →

NCT06777368

Summary

The purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo Transcatheter Aortic Valve Replacement (TAVR).

Eligibility

Age: 18 Years – 105 YearsHealthy volunteers accepted
Inclusion Criteria:

* BVF of a TAV (either Medtronic or Edwards) requiring redo TAVR

Exclusion Criteria:

* BVF due solely to paravalvular regurgitation
* Active endocarditis
* Untreated acute valve thrombosis
* Life-expectancy less than 1-year
* Subject is less than legal age of consent, legally incompetent, or otherwise vulnerable
* Participating in another study that may influence the outcome of this study

Conditions2

Aortic StenosisHeart Disease

Locations70 sites

University of Alabama at Birmingham
Birmingham, Alabama, 35233
Marissa Waite
Abrazo Arizona Heart Hospital
Phoenix, Arizona, 85016
Jessica Byrne
Tucson Medical Center
Tucson, Arizona, 85712
Morgan Torrez
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, 90027
Jaclyn Cordova
Sutter Heatlh
Sacramento, California, 95816
Jessica McCall

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.